TAZ upregulates MIR‐224 to inhibit oxidative stress response in multiple myeloma

Abstract

AbstractBackgroundOxidative stress within the bone marrow niche of multiple myeloma contributes to disease progression and drug resistance. Recent studies have associated the Hippo pathway with miRNA biogenesis and oxidative stress in solid tumors. Oxidative stress and miRNA pathway inter‐relates in several cancers. Our group recently showed that TAZ functions as a tumor suppressor in MM. However, the role of TAZ in oxidative stress in MM is unknown.AimsWe sought to examine the role of TAZ in myeloma cells' response to BM oxidative stress. We postulated that TAZ might be associated with an oxidative stress phenotype and distinct miRNA signature in MM.Methods and ResultsUsing human myeloma cell lines and clinical samples, we demonstrate that TAZ promotes myeloma cells' sensitivity to oxidative stress and anticancer‐induced cytotoxicity by inducing miR‐224 to repress the NRF2 antioxidant program in MM. We show that low expression of TAZ protein confers an oxidative stress‐resistant phenotype in MM. Furthermore, we provide evidence that overexpression of miR‐224 in myeloma cells expressing low amounts of TAZ protein inhibits cell growth and enhances sensitivity to anti‐myeloma therapeutics.ConclusionOur findings uncover a potential role for TAZ in oxidative stress response in MM via the miR‐224‐NRF2 molecular pathway. This provides the scientific ground to explore miR‐224 as a potential molecular target to modify TAZ expression and enhance myeloma sensitivity to treatment.